BACK

Prostate > mCRPC

Clinical trial information


Select trial for more information

Area under investigation,Localized prostate cancer,mCRPC=true,mHSPC,Metastatic prostate cancer

ACTIVATED-4-PC trial overview

Tumor

mCRPC

Trial Identifier

NCT07192614

Phase

I/II

Regimen

AZD6621 monotherapy [administration route 1 (module 1) or administration route 2 (module 2) at recommended dose for expansion 1 and 2 (RDE1 and RDE2)] administration route 1 (module 1) or administration route 2 (module 2) at recommended dose for expansion 2 (RDE2)

Visit ct.gov
Go

AlphaBreak trial overview

Tumor

PSMA-positive mCRPC

Trial Identifier

NCT06402331

Phase

II

Regimen

(225Ac) zadavotide guraxetan monotherapy, IV administration

Visit ct.gov

This study is sponsored by Fusion Pharmaceuticals Inc.

Go

ANDROMEDA trial overview

Tumor

Metastatic prostate cancer

Trial Identifier

NCT07336446

Phase

I/II

Regimen

AZD9750 monotherapy; AZD9750 + saruparib;

Visit ct.gov
Go

APOLLO trial overview

Tumor

mCRPC with prior ARPI and taxane therapy

Trial Identifier

NCT06267729

Phase

I/II

Regimen

AZD0754 (STEAP2 CAR-T) + cyclophosphamide + fludarabine (lymphocyte depleting regimen)

Visit ct.gov
Go

ASCERTAIN trial overview

Tumor

Window of Opportunity (WOO) study in localized prostate cancer deemed suitable for radical prostatectomy

Trial Identifier

NCT05938270

Phase

I

Regimen

Saruparib; darolutamide; saruparib + darolutamide; no treatment arm

Visit ct.gov
Go

CRIUS-1 trial overview

Tumor

Adenocarcinoma of the prostate or neuroendocrine differentiated prostate cancer

Trial Identifier

NCT07529717

Phase

I/II

Regimen

AZD8359

Visit ct.gov
Go

EvoPAR-Prostate01 trial overview

Tumor

mHSPC de novo or recurrent

Trial Identifier

NCT06120491

Phase

III

Regimen

Saruparib + ARPI; placebo + ARPI

Visit ct.gov
Go

EvoPAR-Prostate02 trial overview

Tumor

High-risk BRCAm prostate cancer

Trial Identifier

NCT06952803

Phase

III

Regimen

Saruparib + physician’s choice ADT; placebo + physician’s choice ADT; saruparib + physician’s choice ADT + abiraterone (and prednisone/prednisolone); placebo + physician’s choice ADT + abiraterone (and prednisone/prednisolone)

Visit ct.gov
Go

PETRA trial overview

Tumor

Advanced solid tumors (advanced/metastatic ovarian cancer, HR+/HER2- breast cancer, TNBC, pancreatic cancer, prostate cancer, NSCLC, SCLC, gastric cancer, biliary cancer, cervical cancer, endometrial cancer, CRC, bladder cancer)

Trial Identifier

NCT04644068

Phase

I/IIa

Regimen

Saruparib; saruparib + paclitaxel; saruparib + carboplatin ± paclitaxel; saruparib + T-DXd; saruparib + Dato-DXd; saruparib + camizestrant

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

PETRANHA trial overview

Tumor

Metastatic prostate cancer (mCRPC or mHSPC)

Trial Identifier

NCT05367440

Phase

I/IIa

Regimen

Saruparib + enzalutamide; saruparib + abiraterone acetate; saruparib + darolutamide; saruparib + apalutamide

Visit ct.gov
Go

PROSPECTOR trial overview

Tumor

Metastatic prostate cancer

Trial Identifier

NCT07590934

Phase

Ib/​II

Regimen

Escalating dose levels of palacaparib + (225Ac) zadavotide guraxetan; selected dose of palacaparib + (225Ac) zadavotide guraxetan; (225Ac) zadavotide guraxetan monotherapy; docetaxel

Visit ct.gov
Go

SEACLIFF trial overview

Tumor

mCRPC

Trial Identifier

NCT07181161

Phase

I/IIa

Regimen

AZD0516 monotherapy; AZD0516 + palacaparib (AZD0516 will be administered via IV)

Visit ct.gov
Go

NCT06879041 trial overview

Tumor

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Trial Identifier

NCT06879041

Phase

I

Regimen

AZD2284; AZD2287; AZD2275

Visit ct.gov
Go

TROPION-PanTumor03 trial overview

Tumor

Advanced solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, metastatic urothelial carcinoma, BTCs)

Trial Identifier

NCT05489211

Phase

II

Regimen

Dato-DXd; Dato-DXd + capecitabine or 5-FU; Dato-DXd + prednisone or prednisolone; Dato-DXd + carboplatin + bevacizumab followed by Dato-DXd + bevacizumab; Dato-DXd + bevacizumab + (5-FU + leucovorin or capecitabine); Dato-DXd+ 5-FU/leucovorin or capecitabine + bevacizumab; Dato-DXd + rilvegostomig or carboplatin/cisplatin

Visit ct.gov
Go

VECTRA-01 trial overview

Tumor

PSMA-positive metastatic castration-resistant prostate cancer

Trial Identifier

NCT07611110

Phase

III

Regimen

(225Ac) zadavotide guraxetan; active comparator: investigator's choice of cabazitaxel, abiraterone, enzalutamide, apalutamide, darolutamide, rezvilutamide, radium-223

Visit ct.gov
Go

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-84958 US-109129 DE-92568 Last Updated October 20263/26
©2026 AstraZeneca. All rights reserved.